Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic AB’s partner Eisai presented promising data at the CTAD 2025 conference indicating that continued treatment with lecanemab (Leqembi®) could delay the progression of Alzheimer’s disease by up to 8.3 years in certain patient groups. The findings suggest that early initiation of treatment may significantly slow disease progression, offering hope for improved patient outcomes. Additionally, the subcutaneous formulation of lecanemab, approved for use in the U.S. and under review in Japan, demonstrated bioequivalence to intravenous dosing, maintaining efficacy and safety while offering a more convenient administration option.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases, including Alzheimer’s disease. The company collaborates with partners like Eisai to advance its research and development efforts in this field.
Average Trading Volume: 217,002
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.95B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.